133865-89-1

133865-89-1 structure

Name: Safinamide
Chemical Name: (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
CAS Number: 133865-89-1
Molecular Formula: C₁₇H₁₉FN₂O₂
Molecular Weight: 302.343
Catalog: Biochemical Inhibitor Metabolism MAO inhibitor
Create Date: 2018-04-03 08:00:00
Modify Date: 2026-06-30 18:27:56
Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.IC50 value: 98 nM [1]Target: MAO-BSafinamide (EMD 1195686; FCE 26743; ) is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. In addition, Safinamide (EMD 1195686; FCE 26743; ) is voltage-dependent sodium and calcium channel blocker. Safinamide (EMD 1195686; FCE 26743; ) appears to bind to the batrachotoxin-sensitive site 2 of the voltage-sensitive sodium channels. Safinamide blocks N and L-type calcium channels and inhibits glutamate and aspartate release from synaptic terminals.

Name	(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
Synonyms	Safinamide Crude FCE-28073(R-isomer) Safinamide, >= (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide D4-Safinamide Safranamide (S)-(+)-2-[4-(3-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDE METHANSULFONATE Safinamide, 10 mM in DMSO FCE-28073(R-ISOMER); PNU-151774E; NW-1015 Safinamide Intermediate 2 (4-((3-fluorobenzyl)oxy)benzyl)-L-alanine SafinamideQ: What is Safinamide Q: What is the CAS Number of Safinamide Q: What is the storage condition of Safinamide (2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide Safinamide Impurity D N-{4-[(3-Fluorobenzyl)oxy]benzyl}-L-alaninamide (S)-(+)-2-[4-(3-Fluorobenzyloxy)benzylamino]propanamice methansulfonate Safinamide > 2(S)-[4-(3-Fluorobenzyloxy)benzylamino]propionamide Safinamide Impurity Safinamide //BP Safinamide ,Safinamide base (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanaMide Safinamide Impueity (2S)-2-[[[4-[(3-Fluorophenyl)methoxy]phenyl]methyl]amino]propanamide SAFINAMID Salfenamide Safinamide mesylate Intermediate 2 Safinamide/Safinamide methanesulfonate (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide N2-{4-[(3-Fluorbenzyl)oxy]benzyl}-L-alaninamid ZVY1&M1R DO1R CF &&L or S Form EMD 1195686;FCE 26743;EMD-1195686;EMD1195686;FCE-26743 PropanaMide,2-[[[4-[(3-fluorophenyl)Methoxy]phenyl]Methyl]amino]-, (2S) SAFINAMIDE:(S)-(+)-2-[4-(3-FLUOROBENZYLOXY)BENZYLAMINO]PROPA Safinamide IMP SAFINAMIDE:(S)-(+)-2-[4-(3-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDE METHANSULFONATE

Description	Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.IC50 value: 98 nM [1]Target: MAO-BSafinamide (EMD 1195686; FCE 26743; ) is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. In addition, Safinamide (EMD 1195686; FCE 26743; ) is voltage-dependent sodium and calcium channel blocker. Safinamide (EMD 1195686; FCE 26743; ) appears to bind to the batrachotoxin-sensitive site 2 of the voltage-sensitive sodium channels. Safinamide blocks N and L-type calcium channels and inhibits glutamate and aspartate release from synaptic terminals.
Related Catalog	Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase Research Areas >> Neurological Disease
References	[1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916. [2]. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010 Sep;11(13):2261-8. [3]. Onofrj M, et al. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. [4]. Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs. 2007 Jul;8(7):570-9. [5]. Dal Bo L, et al. Bioassay of safinamide in biological fluids of humans and various animal species. Arzneimittelforschung. 2006;56(12):814-9. http://www.ncbi.nlm.nih.gov/pubmed/17260668

Density	1.2±0.1 g/cm3
Boiling Point	476.7±40.0 °C at 760 mmHg
Melting Point	208-212°
Molecular Formula	C₁₇H₁₉FN₂O₂
Molecular Weight	302.343
Flash Point	242.1±27.3 °C
Exact Mass	302.143066
PSA	64.35000
LogP	2.37
Vapour Pressure	0.0±1.2 mmHg at 25°C
Index of Refraction	1.570